Worldwide Clinical Trials Appoints CFO Amid Record Growth

Robust funding for small to midsized pharmaceutical organizations and biotechs – up 96% from a year agoⁱ – is one of the contributing factors toward Worldwide’s growth. This primary market for Worldwide values the company’s “midsized approach” – the combination of a global infrastructure, scientific and methodological expertise, and a personalized customer service experience.

Tuttle joins Worldwide as an experienced global financial executive, with 30 years of driving business growth and building corporate value for companies like American Materials Company, where he served as CFO, and PPD, Inc., where he held senior leadership positions in global finance and accounting.

“I’m thrilled to welcome Brian as a key member of the team architecting Worldwide’s continued growth strategy,” said Peter Benton, president and chief operating officer for Worldwide. “Small and midsized biotechs are doing important work. They deserve the best CRO experience. Brian’s skill in helping companies thrive during hypergrowth will be invaluable as we rapidly scale, focus investments and ensure we deliver the best customer experience.”

"Having spent more than three decades with companies experiencing transformational growth, all roads have led me to working with Worldwide to deliver on the company’s mission to be the world’s best midsized CRO,” said Tuttle. “Worldwide is primed for continued record growth as the booming small and midsized pharma and biotech market turns to us for our specific blend of scientific, medical and operational expertise and customer service."

Tuttle holds an MBA, master’s in tax accounting and BS in business administration from the University of North Carolina at Chapel Hill.

About Worldwide Clinical Trials

Worldwide Clinical Trials employs 2,000+ professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia-Pacific. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services.

With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit www.worldwide.com.

ⁱ [Source: William Blair, January 19, 2021, Pharmaceutical Outsourcing & Services, CRO 2020 Year End Wrap-up; Key Indicators Point to Robust 2021]

View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005397/en/